The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Q: My doctor heard a new heart murmur and suspected I have a narrowed valve due to aortic stenosis. I feel fine. Why did this ...

Varanasi: A team of skilled doctors at the Cardiology department at the Institute of Medical Sciences (IMS), Banaras Hindu ...

For all news and slides from the THT 2025 meeting, check out our conference page and or tune in to the Heart Sounds podcast ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

A new drug could manage aortic valve stenosis, slowing disease progression and reducing the need for aortic valve surgeries.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...